All In Biotech

NDA 208780 · Legacy

Esbriet

Pirfenidone · Oral · Pyridone

Orphan

Last checked: Nov 20, 2026Latest source record: Feb 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jan 11, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

29 Phase 3, 18 recruiting

FAERS reports

40,844

22,668 serious, 9,477 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ( 1 )

Mechanism: The mechanism of action of pirfenidone in the treatment of IPF has not been established.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ESBRIET · PIRFENIDONE 801MG · TABLET, ORAL · Prescription · TE AB
  • ESBRIET · PIRFENIDONE 267MG · TABLET, ORAL · Prescription · TE AB
  • ESBRIET · PIRFENIDONE 534MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Pirfenidone" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death7,558
  • nausea5,186
  • fatigue3,826
  • diarrhoea3,309
  • decreased appetite3,307
  • dyspnoea3,004
  • weight decreased2,261
  • dizziness2,207
  • cough2,093
  • rash2,048
  • vomiting1,819
  • pneumonia1,794

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20094
201015
20116
201213
201310
2014123
20152,883
20164,177
20172,430
20184,311
20194,319
20205,096
20214,958
20224,745
20233,566
20241,930
20251,287
2026971

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Esbriet (Pirfenidone)

2024 spending

$42.1M

Beneficiaries

719

4,228 claims

Per beneficiary

$58,615

$63.83 per unit

View as table
YearSpending
2020$671,048,018
2021$662,208,170
2022$409,939,065
2023$93,415,756
2024$42,143,982

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 205 on PubMed

Sponsor: Legacy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.